Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment

Aelis Farma has announced the commencement of recruitment for its Phase 2B clinical trial evaluating AEF0217, a potential therapeutic for behavioral and cognitive impairments in individuals with Down syndrome. The trial will include 188 participants aged 16 to 32 from France, Italy, and Spain.

AEF0217 is a first-in-class Signalling Specific inhibitor of the CB1 receptor, aiming to treat cognitive issues in neurodevelopmental disorders through selective inhibition. Previous studies show its promise, demonstrating improvements in adaptive behavior without significant adverse effects.

This randomized, double-blind, placebo-controlled study will measure changes in adaptive behaviors using the Vineland Adaptive Behaviour Scales. Recruitment is anticipated to finish by late 2026, with preliminary results by 2027. Aelis Farma remains financially poised to continue its efforts, signaling a potentially groundbreaking advancement in treating Down syndrome.